New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 16, 2013
08:21 EDTPIPPharmAthene receives FDA notification on SparVax
PharmAthene announced it has received notification from the U.S. Food and Drug Administration that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the company will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
News For PIP From The Last 14 Days
Check below for free stories on PIP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
10:47 EDTPIP High option volume stocks: KOG PIP IPXL ADP EWH
Subscribe for More Information
April 7, 2014
09:02 EDTPIPPharmAthene receives notice advising company of of SparVax anthrax vaccine
PharmAthene announced that it has received notice from the Department of Health and Human Services, Biomedical Advanced Research and Development Authority, advising the company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax program. PharmAthene has been developing SparVax to address a requirement for a modern anthrax vaccine based on state-of-the-art vaccine technology. Phase 1 and Phase 2 clinical trials involving 770 healthy subjects have demonstrated that SparVax appears to be well tolerated and capable of producing an immune response in humans.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use